TNFSF13B, TNF superfamily member 13b, 10673

N. diseases: 282; N. variants: 13
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE The analysis identified a cluster of transcripts associated with Sjögren's foci, including messenger RNAs (mRNAs) for C⁻X⁻C motif chemokine ligand 13 (CXCL13) and B-cell activating factor (BAFF), which dominated the major principal component. 30626116 2019
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE Emerging soluble biomarkers for SS related lymphoma include mediators of B cell growth and germinal center formation such as BAFF, FMS-like tyrosine kinase 3 ligand (Flt-3L) and CXCL13 as well as inflammatory contributors such as inteleukin (IL)-17, IL-18, ASC, LILRA3 and the extracellular lipoprotein-associated phospholipase A2 (Lp-PLA2). 31444033 2019
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE Expression of the DEGs IFNG and BAFF increased in SGs from patients with primary SS, as assessed by focus score. 29927095 2018
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept. 24304965 2014
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE Activation of the type I interferon/B cell-activating factor axis in SS has recently attracted particular attention. 24050623 2014
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease BEFREE Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. 22736090 2013
CUI: C0525045
Disease: Mood Disorders
Mood Disorders 		0.300 Biomarker group PSYGENET BAFF transgenic mice can be used in future studies to test compounds of therapeutic value for the treatment of mood disorders associated with autoimmune diseases. 20185032 2010
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease BEFREE Sjögren's syndrome (SS) is an autoimmune disease characterized by clonal B cell attack of the exocrine glands and dysregulated expression of B cell-activating factor (BAFF). 20408860 2010
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE Finally, BAFF plays a major role in B-cell repopulation after their depletion by rituximab in SS. 20457281 2010
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease LHGDN Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. 18617551 2008
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease LHGDN BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. 17469105 2007
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease LHGDN Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. 18050196 2007
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease BEFREE Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). 17214581 2006
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease LHGDN Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. 16802367 2006
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease LHGDN Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome? 16052575 2005
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease LHGDN Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. 15981083 2005
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease BEFREE Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. 15095277 2004
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 AlteredExpression disease LHGDN Analysis of BLyS plasma levels in Systemic Lupus Erythematosus, Sjogren's Syndrome and Rheumatoid Arthritis (RA) has shown that BLyS is higher in a group of patients than in the controls. 15470519 2004
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease BEFREE We conclude that altered B cell differentiation and tolerance induced by excess BAFF may be central to SS pathogenesis. 11781351 2002
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.300 Biomarker disease MGD
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis 		0.260 Biomarker disease BEFREE B-cell-activating factor (BAFF), a proliferation-inducing ligand (APRIL), and α-defensins are involved in the pathogenesis of native IgAN; however, their role on IgAN recurrence has not been previously analyzed. 30776158 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis 		0.260 Biomarker disease BEFREE We previously showed that oligodeoxynucleotides with CpG (CpG-ODN) and B-cell activation factor (BAFF) are involved in hyperproduction of IgA from tonsillar mononuclear cells of patients with IgAN (IgAN-TMCs). 31088610 2019
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis 		0.260 AlteredExpression disease BEFREE However, plasma BAFF levels were positively associated with serum creatinine, proteinuria, uric acid and group A Streptococcus infection index in patients with IgAN. 28260100 2017
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis 		0.260 Biomarker disease BEFREE These data indicated that TW may be involved in IgA production in the tonsils of IgAN patients, inhibiting IgA class switching in IgAN patients through the cooperative roles of AID, TGF-β1, BAFF, and APRIL, highlighting a promising strategy for therapeutic intervention in IgAN. 29312588 2017
CUI: C0017661
Disease: IGA Glomerulonephritis
IGA Glomerulonephritis 		0.260 AlteredExpression disease BEFREE TLR9 and BAFF: their expression in patients with IgA nephropathy. 24993857 2014